Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
6 Key Takeaways
-
1
FDA approves T-DXd plus pertuzumab for HER2-positive breast cancer.
-
2
Approval is based on DESTINY-Breast09 study results.
-
3
40.7 months median progression-free survival with T-DXd combination.
-
4
15% of patients achieved complete responses.
-
5
Study involved 770 patients, showing efficacy regardless of mutation status.
-
6
Key advancement in more than a decade for HER2-targeted therapy.
Trastuzumab deruxtecan (T-DXd) in combination with pertuzumab has received FDA approval as the first-line treatment for metastatic HER2-positive breast cancer, based on the phase III DESTINY-Breast09 study led by Dr. Sara Tolaney at Dana-Farber Cancer Institute. This combination showed a statistically significant improvement in progression-free survival, extending it to 40.7 months compared to 26.9 months with the current standard treatment. The study highlights the promising outcomes for patients even with varying disease progression conditions.
Listen Tab content
